AIHC

JANUARY 28, 2022

The policies in this IPPS and LTCH PPS final rule build on key priorities to close health care equity gaps and support greater access to life-saving diagnostics and therapies during the COVID-19 public health emergency (PHE) and beyond. billion in FY 2021, or 2.7 billion in FY 2021, or 2.7 percent.

Medicare 52

Medicare Medicare Hospitals Payment Systems 52

SQA

AUGUST 8, 2023

TR 43 was originally published in 2007 and revised in 2013 to address industry feedback. Although this Toolkit provides PCPC’s current thinking on MoCRA, companies should be mindful that MoCRA represents meaningful new authorities that FDA has yet to interpret and apply. TR 43 applies solely to empty glass containers.

FDA 40

FDA Compliance COVID-19 World Health 40

Bill of Health

NOVEMBER 13, 2023

In fact, the majority of Americans do not hold strong trust in our health agencies like FDA and CDC. In my forthcoming article, I argue that our cancer regulatory regimes inadequately protect the public. Privatization of Public Dollars — The siphoning of money by cancer medicine from public health and other public systems.

FDA 307

FDA Public Health Governance 307

SQA

AUGUST 2, 2021

ISO 13688:2013, Protective clothing – General requirements. ISO 13688:2013/AMD 1:2021, Protective clothing — General requirements — Amendment 1. ISO/TS 16976-8:2013, Respiratory protective devices – Human factors – Part 8: Ergonomic factors. United States Food and Drug Administration (FDA) – Guidances for Drugs and Biologics.

FDA 83

FDA COVID-19 Pharmaceutical Industry Hospitals 83

Health Populi

JANUARY 2, 2020

To give you a sense of how health and wellness at CES have grown since 2013, consider Asthmapolis, a pioneer in digital respiratory health. At CES 2013, David Van Sickle, CEO and founder of Asthmapolis, spoke in a CES keynote panel about the usefulness of health data in the cloud.

FDA 127

FDA Public Health Telemedicine 127

Bill of Health

AUGUST 29, 2022

Fuse Brown, Developing a Durable Right to Health Care , 14 Minn. 439, 448 (2013). [15] 15] Emily Parker, Constitutional Obligations for Public Education , Educ. Sugarman, 566 F.2d 2d 817, 825 (2d Cir. 13] San Antonio Indep. Rodriguez, 411 U.S. 1, 35 (1973). [14] 14] Erin C. & Tech.

COVID-19 Vaccine 130

COVID-19 Vaccine COVID-19 Informed Consent Governance 130

Drug & Device Law

MAY 11, 2023

A perusal of amicus briefs drew more than a few “they should know what they are talking about here” responses to groups of food and drug law scholars (as opposed to DDL bloggers), former FDA commissioners, former FDA officials, and former DOJ officials, among others. The appellate brief from FDA bears that out well.

FDA 59

FDA COVID-19 Public Health World Health 59

Drug & Device Law

OCTOBER 20, 2023

FDA/Alliance for Hippocratic Medicine v. LLC litigation, in which an anti-abortion group is seeking to invalidate regulatory actions taken by the FDA with regard to mifepristone , a pharmaceutical FDA-approved for use in the termination of pregnancy to ten weeks, in combination with misoprostol. FDA , 727 F. Danco Labs.,

FDA 59

FDA Pharmaceutical Industry Public Health 59

Drug & Device Law

JUNE 28, 2022

Jackson Women’s Health Org. , June 24, 2022), we fully expect attempts by such states to ban FDA-approved prescription drugs that can be used to bring about abortions by chemical means. But when the FDA has approved a product, states no longer have the power to prohibit their sale or use for FDA-approved indications.

FDA 116

FDA Public Health Federal Policy Doctors 116

Drug & Device Law

SEPTEMBER 22, 2023

Constitution’s Supremacy Clause, it strikes a balance between state and federal power on issues of public health and safety, and raises questions about whether our country’s approach to regulation and litigation makes sense for pharmaceuticals and medical devices (spoiler alert: it doesn’t). 472 (2013) is worth consideration as well.

FDA 105

FDA Public Health 105

Drug & Device Law

DECEMBER 29, 2023

Since the FDA requires pre-approval of any warnings about off-label uses, preemption at some point should have been pre-ordained under the Mensing ( 2011+1 ) independence principle, but off-label use did not really figure in Zofran ’s analysis. The FDA’s five reviews of teratogenic risk all came to the same conclusion.

FDA 105

FDA US Department of Health and Human Services COVID-19 COVID-19 Vaccine 105

Drug & Device Law

FEBRUARY 8, 2024

In Hinton , the plaintiff’s sling was implanted in August 2019, after pretty much all the relevant FDA actions on pelvic mesh devices. There are a few ironies in this discussion coming out of the Fifth Circuit’s decision in Children’s Health Defense v. 23-51067, 2024 WL 244938 (5th Cir. Hippo ) was not mentioned in CHD.

COVID-19 Vaccine 52

COVID-19 Vaccine COVID-19 FDA Public Health 52

Drug & Device Law

OCTOBER 7, 2022

One particular “permanent” implantable contraceptive device has been the subject of litigation for years, even though it was approved by FDA as a class III device. (Our Plaintiff also offered a claim based directly on failure to report adverse events to FDA. Our posts go back for more than six years.) 2022 WL 4536240, *3.

FDA 59

FDA Fraud Doctors Public Health 59

Drug & Device Law

MARCH 2, 2023

Commentators beyond this Blog have described how this bent affects contraceptive choice and public health. As to one defendant, the court looked solely to whether plaintiffs’ claims “arise out of or relate to” contacts with Georgia that began in 2019, even though the implants were in 2011 to 2013. 2023 WL 2111346, *6.

FDA 59

FDA Public Health 59